U.S. Court in DC Rejects Drug Maker’s Challenge to “New Formulation” Definition for Medicaid Rebates
- August 29, 2025
The Centers for Medicare & Medicaid Services (CMS’) broad regulatory definition of “new formulation” of a drug to include new-strength versions for determining Medicaid rebates that pharmaceutical manufacturers owe did not exceed the agency’s statutory authority, the U.S. District Court for the District of Columbia held August 27, rejecting a challenge brought by drug maker Chiesi USA.
ARTICLE TAGS
You must be logged in to access this content.